Photo of David Fishman

David Fishman

  • PROFESSOR Obstetrics, Gynecology and Reproductive Science
Print ProfilePrint Profile


  • MD, University of Texas

  • Residency, OB-GYN
    Yale University School of Medicine

  • Fellowship, Gynecology Oncology
    Yale University School of Medicine


    David A. Fishman, MD is a Professor and Fellowship Director in the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Medicine.  Prior to joining the faculty of the Mount Sinai School of Medicine, he was was Professor of Obstetrics and Gynecology, and Director of Gynecologic Oncology at New York University Medical School.

    An internationally recognized gynecologic oncologist, Dr. Fishman is especially noted for his innovative research on the regulation of ovarian metastasis and in developing new methods for the detection of early stage ovarian carcinoma. He established The National Ovarian Cancer Early Detection Program in 1999 with a grant from the National Cancer Institute and philanthropic support. He is currently the Director of this program.

    Dr. Fishman received his medical degree from Texas Tech School of Medicine and completed his residency and fellowship in Obstetrics and Gynecology and Gynecologic Oncology at the Yale University School of Medicine.

    Dr. Fishman has authored over 230 scientific papers, abstracts, and book chapters and several books on gynecologic malignancies. His research has received awards from the National Institutes of Health, National Cancer Institute, Society of Gynecologic Oncologists, Gynecologic Cancer Foundation, American Cancer Society, the Society for Gynecologic Investigation, Berlex Foundation and multiple philanthropic agencies. He serves as an editor for three journals and ad hoc reviewer for 43 medical and scientific journals and is a member of national and international cancer institute study sections from the National Cancer Institute and Centers for Disease Control to the Royal College of Obstetricians and Gynecologists.

    His membership in many medical and honor societies and patient advocacy groups include the American Gynecologic and Obstetrical Society, Society for Gynecologic Investigation, AOA, the Society of Gynecologic Oncologists and the National Ovarian Cancer Coalition. He frequently lectures worldwide on women's cancers and early detection techniques.

    Dr. Fishman has been named a Castle-Connolly/New York Magazine Top doctor and a New York Times Magazine Super Doctor for the past several years.

    Advancing Early Detection of Early Stage Epithelial Ovarian Cancer


  • 2009 - 2012
    Best Doctors
    New York Magazine

  • 2007 -
    NIH NCI EDRN Award

  • 2006 -
    Honorary Chairman
    Presidents Physician Advisory Board

  • 2005 -
    Shufelt Society Lecturer

  • 2005 -
    American Gynecological and Obstetrical Society Lecturer

  • 2005 -
    Invited Lecturer
    Oncology World Congress

  • 2005 -
    Keynote Lecturer
    Society of Gynecologic Oncologists of Canada

  • 2005 -
    Susan Teck Lecturer
    George Washington University

  • 2005 -

  • 2005 -
    Keynote Lecturer
    University of Wisconsin

  • 2005 -
    American College of Obstetricians and Gynecologists Lecturer


As an academic gynecologic oncologist, Dr. Fishman is committed to the development of a comprehensive multidisciplinary program that would decrease the morbidity and mortality of gynecologic malignancies and improve women's healthcare.

His academic career has focused on the ovarian tumor microenvironment and applying our understanding of the processes of carcinogenesis, invasion, and metastasis to develop relevant biomarkers using proteomic technologies and novel sonographic techniques for early detection, cancer specific therapeutics, and means for chemoprevention.

In 1999 the National Ovarian Cancer Early Detection Program (NOCEDP), for which he serves as Director and Principal Investigator, was initiated by NCI support and has achieved international recognition for the clinical application of innovative basic science regarding ovarian cancer. To date this program has evolved into an international collaborative effort from Sri Lanka to the US of over 200 physicians and scientists dedicated to the development of effective means for the accurate detection of early stage disease, chemoprevention, and cancer specific therapeutics. The NOCEDP represents an integrated program of clinicians, scientists, and institutions with complementary expertise unifying to facilitate early detection, treatment and prevention of ovarian cancer.


Wang FQ, Barfield E, Fishman D. Silencing of VEGFR-2 by RNA Interference Inhibits LPA-induced Invasion. Eur J Cancer 2009;.

Hope JM, Wang FQ, Whyte JS, Ariztia EV, Abdalla W, Long K, Fishman DA. LPA receptor 2 mediates LPA-induced endometrial cancer invasion . Gynecol Oncol 2009; 112: 215-223.

Gogoi R, Kudla M, Gil O, Fishman D. The Activity of Medroxyprogesterone Acetate, an Androgenic Ligand, in Ovarian Cancer Cell Invasion. Reprod Sci 2008 Oct; 15(8): 846-852.

Devine KM, Smicun Y, Hope JM, Fishman DA. S1P induced changes in epithelial ovarian cancer proteolysis, invasion, and attachment are mediated by Gi and Rac. Gynecol Oncol 2008 Aug; 110(2): 237-245.

Fleischer AC, Lyshchik A, Jones HW Jr., Crispens M, Loveless M, Andreotti RF, Williams PK, Fishman DA. Contrast-enhanced transvaginal sonography of benign versus malignant ovarian masses: preliminary findings. J Ultrasound Med 2008 Jul; 27(7): 1011-1018.

Cowden Dahl K, Symowicz J, Ning Y, Gutierrez E, Fishman DA, Adley B, Stack MS, Hudson L. Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent e-cadherin loss in ovarian carcinoma cells. Cancer Res 2008 Jun 15; 68(12): 4606-4613.

Feng W, Marquez RT, Lu Z, Liu J, Lu KH, Issa JP, Fishman DA, Yu Y, Bast RC Jr. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer 2008 Apr; 112(7): 1489-1502.

Gil OD, Lee C, Ariztia EV, Wang FQ, Smith PJ, Hope JM, Fishman DA. Lysophosphatidic acid (LPA) promotes E-cadherin ectodomain shedding and OVCA429 cell invation in an uPA-dependent manner. Gynecol Oncol 2008 Feb; 108(2): 361-369.

Liu C, Shea N, Rucker S, Harvey L, Russo P, Saul R, Lopez MF, Mikulskis A, Kuzdzal S, Golenko E, Fishman D, Vonderheid E, Booher S, Cowen E, Hwang S, Whiteley G. Proteomic Patterns for Classification of Ovarian Cancer and CTCL Serum Samples Utilizing Peak Pairs Indicative of Post-Translational Modifications. Proteomics 2007 Nov; 7(22): 4045-4052.

Smicun Y, Gil O, Devine K, Fishman DA. S1P and LPA have an attachment-dependent regulatory effect on invasion of ovarian cancer cells. Gynecol Oncol 2007 Nov; 107(2): 298-309.

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Fishman did not report having any of the following types of financial relationships with industry during 2014 and/or 2015: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Insurance Information

Mount Sinai Health System (MSHS) physicians - including those employed by MSHS - do not always participate in the same health plans in which MSHS hospitals or facilities participate.

Information regarding insurance participation and billing by this physician may be found on this page or obtained by contacting this provider directly.

Insurance plans that the Mount Sinai Health System hospitals or facilities participate in can be found on the Mount Sinai Health System website.

Edit profile in Sinai Central


1176 5th Avenue
9th Floor
New York, NY 10029

Tel: 212-241-5995
Ruttenberg Cancer Treatment Center

1470 Madison Avenue
3rd Floor
New York, NY 10029

Tel: 212-241-1111
Fax: 212-241-7462
Get Directions

Office Hours:
  • Monday 8:30am - 5:00pm
  • Tuesday 8:30am - 5:00pm
  • Wednesday 9:00am - 5:00pm
  • Thursday 8:30am - 5:00pm
  • Friday 8:30am - 2:00pm
Insurance Plans
  • 1199
  • Aetna U.S. Healthcare
  • Aetna U.S. Healthcare - HMO
  • Beech Street
  • Cigna
  • Devon Health Services
  • Empire Blue Cross/Blue Shield
  • First Health
  • Group Health Insurance (GHI) - HMO
  • Group Health Insurance (GHI) - PPO
  • HIP Commercial
  • HealthNet
  • Magnacare
  • Medicare Part B
  • Multiplan/PHCS
  • Oxford (Medicare)
  • Oxford Freedom
  • Oxford Liberty
  • Pomco
  • United Health Care Commercial
  • United Health Care Empire Plan
  • United Healthcare - Mount Sinai group only
Payment Methods
  • Master Card
  • Visa
  • Discover
  • Personal Check
  • Cash